摘要
目的:观察肝脏胰岛素受体(IR)和胰岛素受体底物-1(IRS-1)表达的改变,探讨罗格列酮防治继发性糖尿病的可能机制。方法:用油酸经胰胆管插管灌注的方法诱导CP,将成模大鼠随机分成模型组、治疗组、对照组,以罗格列酮治疗7d,Westernblots法测定各组大鼠肝细胞IR和IRS-1表达的改变。结果:模型组IR和IRS-1表达较对照组都有明显降低(P<0.05);治疗组IR和IRS-1表达较对照组有不同程度的上调(P<0.05)。结论:胰岛素信号转导异常可能参与了CP继发胰源性糖尿病机制;罗格列酮在防治继发性胰源性糖尿病动物模型方面具有一定治疗作用。
Objective： To observe the changes of expression of hepatocellular insulin receptor （IR） and insulin receptor substrate 1 （IRS-1）,and discuss preventing mechanism of Rosiglitazone on pancreatogenic diabetes. Methods： Chronic pancreatitis rats were induced 6 weeks earlier by oleic acid injection into the pancreatic duct. Model rats, rats treated by Rosiglitazone and sham rats were studied after 7 days treatment. Expressions of IR and IRS-1 were observed by westernblots. Results： Compared with sham operation rats, model rats showed remarkable depression of IR and IRS-1 expression, while rats treated by Rosiglitazone demonstrated up-regulation of hepatocellular IR and IRS-1 compared with this model. Conclusion： Abnormality of insulin signal transduction may play a important role in Overt Pancreatogenic Diabetes derived from Chronic Pancreatitis, Rosiglitazone has therapeutic effect on this model to some degree.
出处
《天津医科大学学报》
2007年第2期177-179,共3页
Journal of Tianjin Medical University
关键词
慢性胰腺炎
胰源性糖尿病
罗格列酮
胰岛素信号转导
动物模型
Chronic pancreatitis
Pancreatogenic diabetes
Rosiglitazone
Insulin signal transduction
Animal model
